Literature DB >> 1067022

Patterns of sarcoidosis in three population groups in New York City.

A S Teirstein, L E Siltzbach, H Berger.   

Abstract

Caucasians in this study group presented in the chronic stage of sarcoidosis more frequently than the Blacks and Puerto-Rican-born. 2) Twenty-eight percent of the Caucasians and 26% of the Blacks who presented in the chronic stage of sarcoidosis, died of pulmonary insufficiency. 3) Puerto-Rican-born women are especially prone to present with erythema nodosum and Stage I radiographic sarcoidosis. 4) Sarcoidosis with extrathoracic organ involvement was more common in Black and Puerto-Rican-born patients than in Caucasians. 5) The size of the Kveim papules was larger in the Black and Puerto-Rican-born patients than among the Caucasians. 6) Two-thirds of all groups were insensitive to tuberculin. 7) The extent and duration of disease at presentation is a major determinant prognosis. 8) Ethnic factors influence the clinical patterns in sarcoidosis, but socioeconomic factors may preclude generalizations based solely upon clinic populations in New York City.

Entities:  

Mesh:

Year:  1976        PMID: 1067022     DOI: 10.1111/j.1749-6632.1976.tb47048.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

Review 1.  The Clinical Features of Sarcoidosis: A Comprehensive Review.

Authors:  Marc A Judson
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

2.  Reduction of sample heterogeneity through use of population substructure: an example from a population of African American families with sarcoidosis.

Authors:  Cheryl L Thompson; Benjamin A Rybicki; Michael C Iannuzzi; Robert C Elston; Sudha K Iyengar; Courtney Gray-McGuire
Journal:  Am J Hum Genet       Date:  2006-08-10       Impact factor: 11.025

3.  Epidemiology of familial sarcoidosis in the UK.

Authors:  D S McGrath; Z Daniil; P Foley; J L du Bois; P A Lympany; P Cullinan; R M du Bois
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.